CDMOs offering Vaccine Manufacturing with Peptide
9 published
9 published CDMOs match Vaccine Manufacturing and Peptide.
Locations in this set include United States, China, United Kingdom, Germany, India, and Singapore.
Capabilities that show up most often in this set: CMC Analytical Development, Process Development, Recombinant Protein Manufacturing, Sterile Fill-Finish & Aseptic Manufacturing, and Monoclonal Antibody (mAb) Manufacturing.
Matching companies
AmbioPharmFDA-inspected peptide API manufacturer offering GMP custom synthesis, process development, analytical method validation, and vaccine peptide manufacturing from preclinical through commercial scale.
Boston Institute of Biotechnology, LLCFull-service CDMO offering cGMP and non-GMP mammalian, microbial, gene therapy, and cell therapy manufacturing from preclinical to commercial scale, with bioreactor capacity up to 50,000L.
Cytovance BiologicsU.S.-based CDMO offering end-to-end biomanufacturing services for antibodies, recombinant proteins, vaccines, and other biologics modalities, with dedicated microbial and mammalian facilities and in-house cell line development capabilities.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Piramal Pharma SolutionsCDMO specializing in HPAPIs, ADCs, peptides, vaccines, and biologics with 4,700+ team members across 15 global sites and 500+ customers. Offers integrated development and manufacturing with backward integration capabilities and global program management.
ROISSterile fill-finish CDMO for biologics, vaccines and ADCs, offering prefilled syringes, cartridges and vials across five US and European sites. It also supports oral solid dose manufacturing and drug substance development.
Richter BioLogicsGermany-based CDMO specializing in GMP-compliant microbial production of recombinant proteins, peptides, plasmid DNA, and bacterial vaccines with bioreactor capacity up to 1,500 litres and regulatory clearance from FDA, EMA, ANVISA, PMDA, and MFDS.
Symbiosis Pharmaceutical ServicesUK-based fill-finish CDMO offering rapid access to GMP aseptic manufacturing for clinical and commercial injectable drug products across mAbs, ATMPs, ADCs, RNA, peptides, vaccines, and small molecules.
Syngene InternationalInnovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.
Markdown mirror: /explore/vaccine-manufacturing/peptide.md